Loading
A phase 3 trial of Durvalumab, Gemcitabine, Gemcitabine + cisplatin, Oxaliplatin, Carboplatin and Cisplatin in biliary tract cancer, run by AstraZeneca, active and no longer recruiting.
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) is a phase 3 interventional study registered as NCT05771480 by AstraZeneca, with 142 participants enrolled, started 2023-08-16 and due to reach its primary completion in 2025-10-02. Interventions recorded: Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin and Gemcitabine + cisplatin + S-1.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Cisplatin and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Cisplatin and the tag pipeline.
Shares Gemcitabine + cisplatin, Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, Gemcitabine, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/